Progestins and uterine leiomyoma

References

• Buttram VC, Reiter RS. Uterine leiomyomata: etiology, symptomatology and management. Fertil Steril 1981;36:433–42
   PubMed Web of Science ®Google Scholar
• Townsend DE, Sparkes RS, Baluda MC, McClelland G. Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis of glucose-6-phosphase dehydrogenase. Am J Obstet Gynecol 1970;107:1168–73
   PubMed Web of Science ®Google Scholar
• Nibert M, Heim S. Uterine leiomyoma cytogenetics. Genes Chromosomes Cancer 1990; 2:3–13
   PubMedGoogle Scholar
• Rein MS, Friedman AJ, Barbieri RL. Cytogenic abnormalities in uterine leiomyomata. Obstet Gynecol 1991;77:923–6
   PubMed Web of Science ®Google Scholar
• Cirkel U, Ochs H, Roehl A, Schneider HPG. Estrogen and progesterone receptor content of enucleated uterine myomata after luteinizing hormone-releasing hormone analogue depot therapy. Acta Obstet Gynecol Scand 1994;73:328–32
   Web of Science ®Google Scholar
• Mettler L, Mayer-Eichberger D, Kienle E, Lipka K. Leuprorelinacetat-Depot zur Behandlung des Uterus myomatosus. Fertilität 1993;9:167–74
   Google Scholar
• Yamamoto T, Takamori K, Okada H. Estrogen biosynthesis in leiomyoma and myometrium of the uterus. Horm Metab Res 1984;16:678–9
   Google Scholar
• Pasqualini JR., Vella CH, Cornier E, et al. Effect of Decapeptyl, an agonistic analog of gonadotropin-releasing hormone on estrogens, estrogen sulfates, and progesterone receptors in leiomyoma and myometrium. Fertil Steril 1990;53:1012–17
   Google Scholar
• Andersen J, Grine E, Eng CLY. Expression of connexin-43 in human myometrium and leio-myomas. Am J Obstet Gynecol 1993;169: 1266–76
   Google Scholar
• Rein MS, Barbieri RL, Friedman AJ. Progester-one: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995;172:14–18
   Google Scholar
• Kawaguchi D, Fujii S, Konishi I, et al. Mitotic activity in uterine leiomyomas during the men-strual cycle. AmJ Obstet Gynecol 1989;160:637–41
   Google Scholar
• Lamminen S, Rantala I, Helin H, et al. Proliferative activity of human uterine leiomyoma cells as mea-sured by automatic image analysis. Gynecol Obstet Invest 1992;34:111–14
   PubMed Web of Science ®Google Scholar
• Harris on-Wo olrych ML, Charnock-Jones DS, Smith SK. Quantification of messenger ribonucleic acid for epidermal growth factor in human myometrium and leiomyomata using reverse transcriptase polymerase chain reaction. J Clin Endocrinol Metab 1994;78:1179–84
   Google Scholar
• Brandon DD, Bethea CL, Strawn EY. Progester-one receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 1998;169:78–85
   Google Scholar
• Buchi KA, Keller PJ. Cytoplasmic progestin recep-tors in myomal and myometrial tissues. Concentra-tions and hormonal dependency. Acta Obstet Gynecol Scand 62:487–92
   Google Scholar
• Vij U, Murugesan K, Laumas KR, Farooq A. Progestin and antiprogestin interactions with pro-gesterone receptors in human myomas. Int J Gynaecol Obstet 1990;31:347–53
   PubMed Web of Science ®Google Scholar
• Segaloff A, Weed JC, Sternberg WH, Parson W. The progesterone therapy of human uterine leiomyomas. J Clin Endocrinol Metab 1949;9: 1273–91
   PubMedGoogle Scholar
• Mixs on WT, Hammond DO. Response of fibromas to a progestin. Am J Obstet Gynecol 1961; 82:754–60
   Google Scholar
• Maheux, R. Treatment of fibroids with the combi-nation of the GnRH agonist goserelin (Zoladex) and hormone replacement therapy. In Shaw RW, ed. Advances in Reproductive Endocrinology. Vol 4. Uterine Fibroids, Time for Review. Carnforth, UK: Parthenon Publishing, 1992:135–46
   Google Scholar
• Ueki M, Okamoto Y, Tsurunaga T, et al. Endocrinological and histological changes after treatment of uterine leiomyomas with danazol or buserelin. J Obstet Gynaecol 1995;21:1–7
   Google Scholar
• De Leo V, Morgante G, Lanzetta D, et al. Danazol administration after gonadotropin-releasing hor-mone analogue reduces rebound of uterine myomas. Hum Reprod 1997;12:357–60
   Google Scholar
• Wallwiener D, Aydeniz B, Rimbach S, et al. Minimal invasive Operationstechniken und GnRH-Analoga Applikation. In Schweppe K.-W, Bastert G, Klosterhalfen B, eds. GnRH-Agonisten in der Behandlung von Endometriose und Uterus myomatosus. Munich: Zuckschwert, 1994:61–6
   Google Scholar
• Hackenb erg, R. Präoperativer Einsatz von Zoladex Gyn beim Uterusmyom. In Schweppe K.-W, Bastert G, Klosterhalfen B, eds. GnRH-Agonisten in der Behandlung von Endometriose und Uterus myomatosus. Munich: Zuckschwert, 1994:52–60
   Google Scholar
• Maheux R, Lemay A, Blanchet P, et al. Maintained reduction of uterine leiomyo ma following addition of hormonal replacement therapy to a monthly luteinizing hormone releasing hormone agonist implant: a pilot study. Hum Reprod 1991;6:500–5
   PubMed Web of Science ®Google Scholar
• Schweppe K-W. GnRH analogues in the treatment of uterine fibroids: results of clinical studies. In Shaw RW, ed. Advances in Reproductive Endocrinology. Vol 4. Uterine Fibroids, Time for Review. Carnforth, UK: Parthenon Publishing, 1992:103–12
   Google Scholar
• Matta WH, Shaw RW, Cambell S. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist buserelin. Fertil Steril 1988;49:1083–5
   Google Scholar
• Kettel LM, Murphy AA, Morales AJ, Yen SS. Clinical effect of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod 1994;9(Suppl 1):16–20
   Google Scholar